| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 428.22 | 47.5% | 0.5% |
| Total Income | 430.31 | 45.9% | 0.3% |
| Expenditure | 430.63 | 13.1% | 24.7% |
| PBT | -0.29 | 99.7% | 100.3% |
| Net Profit | 4.60 | 105.2% | 95.3% |
| OPM | 21.47% | 17.95pp | 21.38pp |
| NPM | 1.07% | 31.14pp | 21.83pp |
| EPS | 0.40 | 94.8% | 95.3% |
Onesource FY26: Revenue ₹14,216 Mn, EBITDA ₹3,042 Mn; FY28 Guidance Reaffirmed
13 May 2026 · 13 May, 1:48 pm
Summary
OneSource Specialty Pharma Limited announced a strong recovery in Q4FY26, with revenue jumping 47% quarter-on-quarter to ₹4,282 million and EBITDA expanding over 5x to ₹919 million. This performance was attributed to broad business momentum and successful semaglutide launches in India. Despite the robust quarterly performance, the full fiscal year 2026 saw a 2% year-on-year revenue decline to ₹14,216 million and a 35% fall in EBITDA to ₹3,042 million. Management expressed confidence in sustaining growth momentum into FY27, citing new product launches and pipeline expansion, while reiterating its ambitious FY28 guidance.
Key Highlights
- 1
Q4FY26 revenue surged by 47% quarter-on-quarter to ₹4,282 million, driven by growth across all service offerings and India semaglutide commercial launches.
- 2
EBITDA for Q4FY26 expanded over 5x quarter-on-quarter to ₹919 million, reflecting operating leverage on higher CSA revenues.
- 3
Adjusted Profit After Tax (PAT) for Q4FY26 stood at ₹390 million, a significant turnaround from a loss in the previous quarter, with an adjusted EPS of ₹3.4.
- 4
For the full fiscal year 2026, revenue was ₹14,216 million, marking a slight decline of 2% year-on-year.
- 5
FY26 EBITDA decreased by 35% year-on-year to ₹3,042 million, with the EBITDA margin at 21%.
- 6
Adjusted PAT for FY26 was ₹739 million, a 68% decrease year-on-year, resulting in an adjusted EPS of ₹6.5.
- 7
OneSource reaffirmed its FY28 guidance, targeting approximately $400 million in organic revenue with an EBITDA margin of around 40%.
Management Comments
Neeraj Sharma
We saw a strong recovery in Q4 driven by broad-based business performance. The quarter was marked by successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses. With the recent back-to-back semaglutide approvals in Canada and continued expansion of our biologics pipeline, we are well positioned to sustain growth momentum into FY27.
Informational and educational content only. Not investment advice.